Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Calvin Chao

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
The Oncologist|April 9, 2014
Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patientsGeetika Srivastava, Lindsay A Renfro, Robert J Behrens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2025
Molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): using real-world data to describe this unique clinical entityAndrew A Davis, Ellen Jaeger, Ian S Hagemann, et al.
Journal of the National Cancer Institute|March 15, 2026
Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genesSiddhartha Yadav, Sonya Reid, Binyam Yilma, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2016
Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer PatientsBaruch Brenner, Ravit Geva, Megan Rothney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE StudyTakeharu Yamanaka, Eiji Oki, Kentaro Yamazaki, et al.
Breast Cancer Research and Treatment|July 1, 2017
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialUlrike Nitz, Oleg Gluz, Matthias Christgen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2013
Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancerVered Stearns, Lisa K Jacobs, Maryjo Fackler, et al.
Breast Cancer Research and Treatment|January 12, 2019
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialUlrike Nitz, Oleg Gluz, Matthias Christgen, et al.
JCO Global Oncology|June 28, 2021
Substantial Reduction in Adjuvant Chemotherapy With the Use of the 21-Gene Test to Manage Early Breast Cancer in a Public Hospital in BrazilAndré Mattar, Guilherme R Fonseca, Murilo B A Romão, et al.
Breast Cancer Research and Treatment|September 23, 2018
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS studyHiroji Iwata, Norikazu Masuda, Yutaka Yamamoto, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
The Oncologist|April 9, 2014
Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patientsGeetika Srivastava, Lindsay A Renfro, Robert J Behrens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2025
Molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): using real-world data to describe this unique clinical entityAndrew A Davis, Ellen Jaeger, Ian S Hagemann, et al.
Journal of the National Cancer Institute|March 15, 2026
Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genesSiddhartha Yadav, Sonya Reid, Binyam Yilma, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2016
Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer PatientsBaruch Brenner, Ravit Geva, Megan Rothney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE StudyTakeharu Yamanaka, Eiji Oki, Kentaro Yamazaki, et al.
Breast Cancer Research and Treatment|July 1, 2017
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialUlrike Nitz, Oleg Gluz, Matthias Christgen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2013
Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancerVered Stearns, Lisa K Jacobs, Maryjo Fackler, et al.
Breast Cancer Research and Treatment|January 12, 2019
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialUlrike Nitz, Oleg Gluz, Matthias Christgen, et al.
JCO Global Oncology|June 28, 2021
Substantial Reduction in Adjuvant Chemotherapy With the Use of the 21-Gene Test to Manage Early Breast Cancer in a Public Hospital in BrazilAndré Mattar, Guilherme R Fonseca, Murilo B A Romão, et al.
Breast Cancer Research and Treatment|September 23, 2018
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS studyHiroji Iwata, Norikazu Masuda, Yutaka Yamamoto, et al.
Pageof 4